西黄丸联合CAF方案治疗晚期乳腺癌患者的增效减毒效果观察

The effect-enhancing and toxicity-reducing effects of Xihuang Pill combined with CAF regimen on patients with advanced breast cancer

目的:研究西黄丸联合CAF方案治疗晚期乳腺癌患者的增效减毒效果。方法:选取我院2014年2月至2016年2月98例晚期乳腺癌患者为研究对象,将纳入患者抽签随机分为观察组与对照组,每组49例。对照组给予单纯CAF方案治疗,观察组在CAF方案基础上加用西黄丸,比较两组凝血功能、免疫功能、肿瘤标志物、临床疗效、毒副反应。结果:观察组总有效率48.98%,明显高于对照组28.57%。治疗2个月后,观察组癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)分别为(12.15±6.93)μg/L、(16.77±8.96)U/ml、(15.41±8.22)U/ml,均明显优于对照组(19.21±8.78)μg/L、(26.29±12.67)U/ml、(23.02±10.64)U/ml,观察组CD3+、CD4+、CD8+、CD4+/CD8+分别为(68.19±6.25)%、(36.42±5.95)%、(27.89±6.38)%、(1.29±0.46)%,均优于对照组(61.24±6.65)%、(32.73±4.70)%、(31.19±7.06)%、(1.07±0.39)%,观察组活化部分凝血活酶时间(APPT)、凝血酶原时间(PT)、纤维蛋白原(FIB)、血小板计数(PLT)分别为(32.82±5.78)s、(11.84±2.56)s、(3.11±1.34)g/L、(230.6±50.3)×109/L,均优于对照组(29.10±4.27)s、(9.72±2.02)s、(3.94±1.78)g/L、(271.3±44.6)×109/L。观察组恶心呕吐、胃肠道反应、血小板减少、白细胞减少发生率显著低于对照组(P<0.05)。结论:西黄丸联合CAF方案治疗晚期乳腺癌可以缓解血液高凝状态,增强免疫机能,杀灭肿瘤细胞同时减轻毒副反应。

Objective： To study the effect-enhancing and toxicity-reducing effects of Xihuang Pill combined with CAF regimen on patients with advanced breast cancer. Methods： 98 cases of patients with advanced breast cancer treated in our hospital during February 2014 to February2016 were selected,and they were randomly divided into the observation group and the control group,49 cases in each group. Patients in the control group were treated with CAF regimen alone while those in the observation group were treated with CAF regimen combined with Xihuang pill. The coagulation function,immune function,tumor markers,clinical efficacy and side effects were compared between two groups.Results： After 2 months of treatment,the total effective rate in the observation group was 48. 98%,higher than that in the control group with28. 57%（P〈0. 05）. After 2 months of treatment,levels of CEA,CA125 and CA153 in the observation group were（12. 15 ± 6. 93） μg/L,（16. 77 ± 8. 96） U/ml,（15. 41 ± 8. 22） U/ml,better than those in the control group（19. 21 ± 8. 78） μg/L,（26. 29 ± 12. 67） U/ml,（23. 02 ±10. 64） U/ml（all P〈0. 05）. After 2 months of treatment,CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋in observation group were（68. 19 ± 6. 25） %,（36. 42 ± 5. 95） %,（27. 89 ± 6. 38） %,（1. 29 ± 0. 46） %,better than those in the control group（61. 24 ± 6. 65） %,（32. 73 ± 4. 70） %,（31. 19 ± 7. 06） %,（1. 07 ± 0. 39） %（all P〈0. 05）. After 2 months of treatment,APPT,PT,FIB and PLT in the observation group were（32. 82 ± 5. 78） s,（11. 84 ± 2. 56） s,（3. 11 ± 1. 34） g/L,（230. 6 ± 50. 3） × 10^9/L,better than those in the control group（29. 10 ± 4. 27） s,（9. 72 ± 2. 02） s,（3. 94 ± 1. 78） g/L,（271. 3 ± 44. 6） × 109/L（all P〈0. 05）. Incidence rates of nausea,vomiting,gastrointestinal reactions,thrombocytopenia and hypoleucocytosis in the observation group were significantly lower than those in the control group（P〈0. 05）.Conclusion： The application of Xihuang pill combined with CAF regimen in the treatment of advanced breast cancer can relieve the blood hypercoagulable state,enhance the immune function,inhibit and kill tumor cells and reduce side effects.